Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "The distinction between treating obesity and treating diabetes with the same molecule reflects regulatory and insurance frameworks, not differences in the medicine itself." Efficacy Across Populations: What the Broader SURMOUNT and SURPASS Programs Show The SURMOUNT program extends beyond its first trial
Suppliers who take the time to learn about your unique needs become true partners in the success of your product, whether you need early finding screening, formulation improvement, or commercial-scale manufacturing
Navigating the newest FDA-approved medications doesn't have to be confusing
Fat-dissolving is an inflammatory process it needs time to work & recover
How to Make Sure Your Scan Results Are Clear If youre using Ozempic, Wegovy, or Mounjaro and are scheduled for a scan, its helpful to mention your medication to the radiology or imaging team